Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Ambit Biosciences Corp (AMBI)

NASDAQ
Currency in USD
Disclaimer
15.60
0.00(0.00%)
Closed
Fair Value
Unlock Value
Day's Range
15.4016.25
52 wk Range
0.0016.25
Prev. Close
15.6
Open
15.4
Day's Range
15.4-16.25
52 wk Range
0-0
Volume
0
Average Vol. (3m)
171,366
1-Year Change
0%
Shares Outstanding
18,002,000
Fair Value
Unlock
Dividends Payment Streak
Unlock
Technical
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Daily
Weekly
Monthly
More
How do you feel today about AMBI?
Vote to see community's results!
or

Ambit Biosciences Corp Company Profile

Ambit Biosciences Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of oncology, autoimmune, and inflammatory diseases in the United States. The company’s products include quizartinib, an orally administered FMS-like tyrosine kinase inhibitor that has completed Phase II clinical trials for the treatment of patients with relapsed and refractory acute myeloid leukemia. Its drug candidates also comprise AC410, a small molecule inhibitor of Janus kinase 2, which is in Phase 1 clinical trials; and AC708, a receptor tyrosine kinase inhibitor that is in pre-clinical studies for the treatment of oncology, autoimmune, and inflammatory diseases. The company has collaboration agreements with Astellas Pharma Inc. to research, develop, and commercialize various FLT3 kinase inhibitors; Cephalon, Inc. to identify and develop clinical candidates that target the BRAF kinase and a second kinase; and Genoptix, Inc. to develop a laboratory diagnostic test to identify patients that harbor ITD mutations in their FLT3 receptor tyrosine kinase. Ambit Biosciences Corporation was formerly known as Aventa Biosciences Corporation and changed its name to Ambit Biosciences Corporation in November 2001. The company was incorporated in 2000 and is based in San Diego, California. As of November 10, 2014, Ambit Biosciences Corporation operates as a subsidiary of Daiichi Sankyo Company, Limited.

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.